Scotland's NICE dislikes GSK's Anoro

Share this article:

Scotland's version of NICE, the Scottish Medicines Consortium (SMC), says two COPD drugs are not worth the Scottish National Health Service's money.

Among the drugs Regulatory Focus found on the SMC's “not recommended” list were GlaxoSmithKline's Anoro (umeclidinium/vilantero) and Boehringer Ingelheim's Striverdi Respimat (olodaterol).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters